Tag: Xarelto
New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus aspirin following lower extremity revascularisation
Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-...
Positive NICE recommendation for Xarelto to prevent atherothrombotic events in CAD and PAD patients
The National Institute for Health and Care Excellence (NICE) has published the final appraisal deter...
Rivaroxaban recommended by NICE for peripheral and coronary artery disease patients
The National Institute for Health and Care Excellence (NICE) in the UK has published a positive draf...
Rivaroxaban gets FDA approval for treatment in CAD or PAD
Rivaroxaban, brand name Xarelto (Janssen), has received approval by the US Food and Drug Adminis...
Bayer announces new licensed indication for use of Xarelto in patients with coronary artery disease
Xarelto, co-administered with aspirin, is indicated in the EU for the prevention of atherothromb...
Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary artery disease
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Janssen seeks approval for rivaroxaban to be used to reduce cardiac events
Janssen has submitted a supplemental new drug application to the US FDA for two new indications ...
ESC 2017: Rivaroxaban significantly lowers risk of stroke, cardiovascular death, and myocardial infarction in patients with coronary artery disease
The COMPASS study, which was presented at the European Society of Cardiology (ESC) congress (26–...
European Medicines Agency issues positive opinion for rivaroxaban
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
ACC 2017: Dual anti-thrombotic approach has similar risk of bleeding to dual antiplatelet therapy
The GEMINI-ACS study, which was simultaneously presented at the 2017 scientific sessions of the ...
COMPASS study of rivaroxaban to end early for efficacy
The phase three COMPASS trial, evaluating the efficacy and safety of rivaroxaban (Xarelto, Bayer) fo...
AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients with atrial fibrillation
Two drug regimens involving low doses of rivaroxaban (Xarelto, Bayer)—one with a 15mg once daily...
